Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Biotechnology

Healthcare
$16.99 +0.58%

+$0.04 today

Market cap
$3.10B
Beta
0.90
P/E (TTM)
98.7
EPS (TTM)
$0.07
52W Low $4.40High $10.08

Volume 2.76M

Average 1.66M

XERS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Xeris Biopharma Holdings, Inc.NASDAQ: XERS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $8.78M rose 13.3% year over year, behind the +26.3% change in trailing-twelve-month research & development. Sequentially, it rose 11.5% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.

Context

  • Research & development amounted to 10.7% of revenue in FY2025, down 1.9 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +13.3% toward the trailing-twelve-month pace of +26.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.78M+11.5% QoQ
Last fiscal yearDec 2025
$31.17M+21.9% YoY
LTMMar 2026
$32.2M+26.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.3%——
1 year+21.9%——
3-year CAGR+14.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
31.17M USD
Year-over-year change
+21.9%
4-year CAGR
+5.5%

Research & Development vs competitors

How XERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +26.3% is the 6th highest of 9, against a peer median of +31.1%.
  • Research & development amounts to 10.2% of revenue for XERS, versus a peer median of 22.7%.
XERS Competitors
Research & Development for XERS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ASNDAscendis Pharma A/SLTM Sep 2026€274.3M EUR-10.0%-9.3%22.7%
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$253.86M USD+1.2%+24.8%30.6%
SEPNSepterna, Inc.LTM Sep 2026$132.66M USD+56.0%—137.8%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$101.27M USD+35.7%+54.7%—
MNKDMannKind CorporationLTM Mar 2026$72.56M USD+54.7%+49.8%20.1%
GHRSGH Research PLCLTM Mar 2026$43.27M USD+26.5%+23.7%—
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$32.2M USD+26.3%+14.1%10.2%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$16.69M USD-64.4%-17.8%—
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$8.48M USD+125.2%+24.8%9.8%
Peer median (excluding XERS) —+31.1%+24.8%22.7%

Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.59M110.25M163.91M203.07M291.85M
Cost of Revenue13.32M22.63M28.65M36.83M53.41M
Gross Profit36.27M87.61M135.27M166.24M238.43M
Gross Margin73.1%79.5%82.5%81.9%81.7%
Research & Development25.16M20.97M22.34M25.56M31.17M
Selling, General & Admin125.72M137.75M146.1M163.48M182.37M
Operating Expenses151.43M169.55M179.28M199.88M213.54M
Depreciation & Amortization1.88M12.67M13.16M12.63M12.16M
EBITDA(113.67M)(69.31M)(23.74M)(13.99M)12.71M
EBITDA Margin-229.2%-62.9%-14.5%-6.9%4.4%
Operating Income(115.16M)(81.94M)(44.01M)(33.65M)24.9M
Operating Margin-232.2%-74.3%-26.8%-16.6%8.5%
Interest Income313K2.58M4.75M5.32M4.74M
Interest Expense7.18M14.1M26.61M33.18M29.08M
Other Income / Expenses(7.57M)(14.14M)(19.49M)(23.46M)(24.34M)
Income Before Tax(122.73M)(96.08M)(63.5M)(57.1M)554K
Pre-Tax Margin-247.5%-87.2%-38.7%-28.1%0.2%
Income Tax Expense0(1.42M)(1.25M)(2.27M)0
Net Income(122.73M)(94.66M)(62.26M)(54.84M)554K
Net Margin-247.5%-85.9%-38.0%-27.0%0.2%
EPS (Basic)(1.55)(0.70)(0.45)(0.37)0.00
EPS (Diluted)(1.55)(0.70)(0.45)(0.37)0.00
Weighted Avg Shares79.03M135.63M137.67M146.77M160.43M
Weighted Avg Shares (Diluted)79.03M135.63M137.67M146.77M172.74M

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Intrinsic Alpha fair value

Locked

Current Price

$16.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.